SOLESENCE, INC.
Business
Solésence, Inc. develops and manufactures health care solutions for beauty, health, and wellness, with skin health as the core focus. The company offers finished consumer products including skin care, sun care, and color cosmetics sold to brand partners under their names, plus active pharmaceutical ingredients for personal care applications. Products are manufactured using proprietary coating and dispersion technologies and sold globally to prestige and mass-market beauty brands.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 62 | 52 | 37 | 37 | 29 | |
| Cost of revenue | 46 | 36 | 29 | 29 | 21 | |
| Gross profit | 16 | 16 | 8 | 8 | 9 | |
| Research and development expense | 4 | 4 | 4 | 3 | 2 | |
| Selling, general and administrative expense | 10 | 7 | 8 | 8 | 4 | |
| Net income from operations | 2 | 5 | −4 | −2 | 3 | |
| Interest expense, net | 931,000 | 670,000 | — | — | — | |
| Other income, net | 1 | — | — | — | — | |
| Net income before provision for income taxes | 2 | 4 | −4 | −3 | 2 | |
| Provision for income taxes | 73,000 | 227,000 | 6,000 | −17,000 | 37,000 | |
| Net income | 2 | 4 | −4 | −3 | 2 | |
| Net income per share-basic | 0.03 | 0.07 | −0.09 | −0.05 | 0.05 | |
| Weighted average number of basic common shares outstanding | 70 | 62 | 50 | 49 | 45 | |
| Net income per share-diluted | 0.02 | 0.07 | −0.09 | −0.05 | 0.05 | |
| Weighted average number of diluted common shares outstanding | 73 | 65 | 50 | 49 | 47 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 1 | 1 | 2 | 2 | 657,000 | |
| Trade accounts receivable | 8 | 6 | 4 | 5 | — | |
| Allowance for credit losses | −806,000 | −786,000 | −225,000 | −139,000 | 0 | |
| Trade accounts receivable, net | 7 | 5 | 3 | 5 | 4 | |
| Inventories, net | 19 | 20 | 10 | 9 | 6 | |
| Prepaid expenses and other current assets | 2 | 3 | 1 | 866,000 | 910,000 | |
| Total current assets | 29 | 29 | 16 | 17 | 12 | |
| Equipment and leasehold improvements, net | 14 | 13 | 9 | 8 | 5 | |
| Operating leases, right of use | 7 | 8 | 8 | 9 | 12 | |
| Other assets, net | 37,000 | 3,000 | 4,000 | 6,000 | 8,000 | |
| Total assets | 50 | 50 | 33 | 34 | 28 | |
| Line of credit accounts receivable, related party | 5 | — | 3 | 4 | 1 | |
| Current portion of line of credit inventory, related party | — | 4 | — | — | — | |
| Current portion of term debt, related party | — | 1 | 2 | — | — | |
| Current portion of operating lease obligations | 1 | 1 | 1 | 0 | 589,000 | |
| Accounts payable | 4 | 9 | 6 | 6 | 4 | |
| Deferred revenue | 930,000 | 6 | 2 | 2 | 783,000 | |
| Accrued expenses | 3 | 5 | 869,000 | 1 | 946,000 | |
| Total current liabilities | 14 | 26 | 16 | 14 | 7 | |
| Long-term portion of operating lease obligations | 8 | 9 | 9 | 10 | 12 | |
| Long-term line of credit inventory, related party | 10 | — | 5 | 3 | — | |
| Long-term debt, related party | 1 | — | 1 | 1 | — | |
| Asset retirement obligations | 194,000 | 246,000 | 238,000 | 230,000 | 222,000 | |
| Total long-term liabilities | 18 | 9 | 15 | 14 | 14 | |
| Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding | — | — | — | — | — | |
| Common stock, $.01 par value, 95,000,000 shares authorized; 70,614,045 and 70,103,279 shares issued and outstanding on December 31, 2025 and 2024, respectively | 706,000 | 700,000 | 496,000 | 493,000 | 489,000 | |
| Additional paid-in capital | 116 | 115 | 106 | 105 | 104 | |
| Accumulated deficit | −99 | −100 | −105 | −100 | −97 | |
| Total stockholders equity | 18 | 15 | 2 | 6 | 7 | |
| Total liabilities and stockholders equity | 50 | 50 | 33 | 34 | 28 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 897,000 | 928,000 | 742,000 | 567,000 | 454,000 | |
| Stock-based compensation | 575,000 | 725,000 | 773,000 | 625,000 | 160,000 | |
| Trade accounts receivable, net | −2 | −1 | 1 | −797,000 | −1 | |
| Inventories, net | 2 | −10 | −1 | −3 | −2 | |
| Prepaid expenses and other assets | 662,000 | −2 | −216,000 | 44,000 | −304,000 | |
| Accounts payable | −5 | 2 | −503,000 | 2 | 1 | |
| Deferred revenue | −5 | 3 | 165,000 | 744,000 | 1 | |
| Accrued expense | −2 | 4 | −146,000 | 77,000 | 481,000 | |
| Change in right of use asset and lease liability, net | −240,000 | −163,000 | 2 | 631,000 | −40,000 | |
| Net cash (used in) provided by operating activities | −9 | 2 | −2 | −2 | 2 | |
| Acquisition of equipment and leasehold improvements | −2 | −5 | — | — | — | |
| Net cash used in investing activities | −2 | −5 | −1 | −3 | −2 | |
| Proceeds from line of credit - inventory, related party | 6 | 200,000 | — | — | 500,000 | |
| Payments to line of credit - inventory, related party | — | −1 | — | — | −1 | |
| Net proceeds from line of credit accounts receivable, related party | 5 | — | — | — | — | |
| Net payments to line of credit accounts receivable, related party | — | −3 | — | −30 | −26 | |
| Payments to term loans, related party | — | −2 | −1 | — | — | |
| Proceeds from issuance of mezzanine preferred stock | — | 6 | — | — | — | |
| Proceeds from issuance of stock and exercise of stock options | 323,000 | 2 | — | — | — | |
| Net cash provided by financing activities | 11 | 2 | 3 | 6 | −747,000 | |
| Decrease in cash | −121,000 | −313,000 | −464,000 | 2 | −300,000 | |
| Cash paid for interest | 1 | 637,000 | 752,000 | 333,000 | 218,000 | |
| Federal income taxes paid | — | — | — | — | — | |
| State income taxes paid | 325,000 | — | — | — | — | |
| Accounts payable incurred for the purchase of equipment and leasehold improvements | 382,000 | 434,000 | 400,000 | 971,000 | 414,000 | |
| Conversion of mezzanine preferred stock | — | 6 | — | — | — | |
| Right-of-use asset obtained in exchange for a lease liability | 430,000 | 1 | 182,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is SOLESENCE, INC.'s CIK number?
SOLESENCE, INC.'s SEC CIK number is 0000883107 (883107). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find SOLESENCE, INC.'s SEC filings?
All of SOLESENCE, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did SOLESENCE, INC. last report earnings?
SOLESENCE, INC. (SLSN) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-003273). This is SOLESENCE, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is SOLESENCE, INC.'s most recent earnings 8-K?
SOLESENCE, INC.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001171843-26-003273. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View SOLESENCE, INC.'s latest earnings 8-K →
Look up any company's CIK number →